Equities Analysts Set Expectations for CNTA Q3 Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Centessa Pharmaceuticals in a research note issued to investors on Monday, March 24th. Leerink Partnrs analyst D. Risinger anticipates that the company will earn ($0.40) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($2.06) EPS and FY2029 earnings at $0.49 EPS.

A number of other brokerages have also issued reports on CNTA. Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a research note on Wednesday. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $26.00.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $14.59 on Thursday. Centessa Pharmaceuticals has a 52-week low of $7.75 and a 52-week high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -9.54 and a beta of 1.54. The business’s 50 day moving average is $16.48 and its two-hundred day moving average is $16.41.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of Centessa Pharmaceuticals by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 57,257 shares of the company’s stock valued at $959,000 after purchasing an additional 660 shares during the period. GAMMA Investing LLC grew its holdings in Centessa Pharmaceuticals by 29.1% in the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at approximately $31,000. Barclays PLC raised its stake in Centessa Pharmaceuticals by 1,414.9% during the 4th quarter. Barclays PLC now owns 5,302 shares of the company’s stock valued at $89,000 after acquiring an additional 4,952 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after acquiring an additional 5,316 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Centessa Pharmaceuticals news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the sale, the general counsel now directly owns 118,265 shares in the company, valued at approximately $1,808,271.85. This trade represents a 4.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $16.34, for a total transaction of $163,400.00. Following the transaction, the insider now owns 134,021 shares of the company’s stock, valued at $2,189,903.14. This represents a 6.94 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 260,168 shares of company stock valued at $4,309,568. Company insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.